Warren W C, Byatt J C, Huynh M, Paik K, Pegg G, Staten N R
Agricultural Sector, Monsanto Company, St. Louis, MO 63198, USA.
Life Sci. 1999;65(25):2755-67. doi: 10.1016/s0024-3205(99)00544-5.
Studies have shown that bovine placental lactogen (bPL) has partial somatogenic activity in vivo even though binding results clearly indicate bPL does not cause homodimerization of the bovine somatotropin receptor (bST-R). To help understand the receptor binding versus biological activity of bovine somatotropin (bST) and bPL we have developed a homologous model system. Full length bST-R was stably transfected into a murine lymphoid cell line, Ba/F3 and a hamster kidney cell line, BHK. From both transfected cell lines, clones were isolated (Ba/F3-C1 and BHK-24) which demonstrated specific binding of bST and, or bPL. Bovine ST stimulated proliferation of the Ba/F3-C1 clonal line over a dose range of 10 to 3000 pM with an EC50 of 100 pM. A bST variant (des 1-4 bST) and porcine ST (pST) which both have approximately 10% of the binding affinity for bST-R as native bST were 1 and 10% as potent as bST in this bioassay, respectively. This suggests that affinity and biological activity are correlated for this system. Proliferation was initiated through the bST-R because addition of a monoclonal antibody which recognizes the extracellular domain of bST-R and inhibits binding of bST to its receptor, inhibited bST-stimulated mitosis. However, even though the affinity of bPL for the bST-R is similar to that of bST, bPL antagonized the proliferative action of bST with an IC50 of 1 nM. Components of the somatogenic signal transduction pathway were also evaluated in both cell lines. Addition of bST to the cell cultures increased phosphorylation of JAK2 in Ba/F3-C1 and BHK-24 cells in a dose-responsive manner but bPL failed to increase phosphorylation of JAK2 in either cell line. In summary, these data support the hypothesis that ST-R homodimerization is necessary for bioactivity in this model system but fail to explain apparent somatogenic activity of bPL in vivo.
研究表明,牛胎盘催乳素(bPL)在体内具有部分促生长活性,尽管结合结果清楚地表明bPL不会导致牛生长激素受体(bST-R)的同源二聚化。为了帮助理解牛生长激素(bST)和bPL的受体结合与生物活性,我们开发了一个同源模型系统。全长bST-R被稳定转染到小鼠淋巴细胞系Ba/F3和仓鼠肾细胞系BHK中。从这两种转染细胞系中分离出克隆(Ba/F3-C1和BHK-24),它们表现出bST和/或bPL的特异性结合。牛生长激素在10至3000 pM的剂量范围内刺激Ba/F3-C1克隆系的增殖,EC50为100 pM。一种bST变体(缺失1-4位的bST)和猪生长激素(pST)对bST-R的结合亲和力约为天然bST的10%,在该生物测定中其效力分别为bST的1%和10%。这表明该系统中亲和力与生物活性相关。增殖是通过bST-R启动的,因为添加一种识别bST-R细胞外结构域并抑制bST与其受体结合的单克隆抗体,会抑制bST刺激的有丝分裂。然而,尽管bPL对bST-R的亲和力与bST相似,但bPL以1 nM的IC50拮抗bST的增殖作用。还在这两种细胞系中评估了促生长信号转导途径的成分。向细胞培养物中添加bST以剂量反应方式增加了Ba/F3-C1和BHK-24细胞中JAK2的磷酸化,但bPL未能增加任一细胞系中JAK2的磷酸化。总之,这些数据支持以下假设,即ST-R同源二聚化对于该模型系统中的生物活性是必要的,但未能解释bPL在体内明显的促生长活性。